KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Non-Current Liabilities: 2017-2025

Historic Total Non-Current Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $165.6 million.

  • Aquestive Therapeutics' Total Non-Current Liabilities rose 8.00% to $165.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.6 million, marking a year-over-year increase of 8.00%. This contributed to the annual value of $159.2 million for FY2024, which is 1.67% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Total Non-Current Liabilities stood at $165.6 million, which was up 0.84% from $164.2 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Total Non-Current Liabilities peaked at $173.6 million during Q4 2022, and registered a low of $112.0 million during Q1 2021.
  • Its 3-year average for Total Non-Current Liabilities is $161.0 million, with a median of $161.6 million in 2023.
  • As far as peak fluctuations go, Aquestive Therapeutics' Total Non-Current Liabilities skyrocketed by 44.90% in 2021, and later dropped by 6.74% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $141.6 million in 2021, then rose by 22.56% to $173.6 million in 2022, then dropped by 6.74% to $161.9 million in 2023, then decreased by 1.67% to $159.2 million in 2024, then grew by 8.00% to $165.6 million in 2025.
  • Its last three reported values are $165.6 million in Q3 2025, $164.2 million for Q2 2025, and $160.9 million during Q1 2025.